Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2014—Qiagen last year enrolled molecular diagnostics laboratories in an early access program to complete the development of a Web-based solution to deliver faster, easier-to-use, and high-confidence clinical interpretation and reporting of observed gene variants in data from NGS-based tests.
March 2014—Clarient Diagnostic Services, a GE Healthcare company, has modified its facility in Houston to support a full range of clinical diagnostic testing for cancer. The facility, which operates under the name SeqWright Genomic Services, is a CLIA-certified lab offering nucleic acid sequencing and genomics services.
Definiens received the 2013 Global Frost & Sullivan Award for Company of the Year for Global Tissue Diagnostics and Pathology Imaging Solutions.
March 2014—Audit MicroControls added the Linearity FD D-Dimer PathFast Immunoanalyzer, five levels, to its line of calibration verification/linearity products. It is intended to simulate human patient serum samples for the purpose of determining linearity, calibration verification, and verification of reportable range for D-dimer.
March 2014—Israeli scientist Michael Yartsev, PhD, CV Starr postdoctoral research fellow of the Princeton Neuroscience Institute at Princeton University, won the 2013 Eppendorf & Science Prize for Neurobiology. Dr. Yartsev uses an unusual animal model—the bat—to study the underlying neural mechanisms of spatial memory and navigation in the mammalian brain.
March 2014—The Center for Phlebotomy Education will conduct intensive three-day seminars in Indianapolis and San Francisco for those who train or manage phlebotomists. The event will provide strategies to help attendees reduce expenses by cultivating satisfied, long-term employees; cut costs through process improvement; nurture professionalism and responsibility among specimen-collection personnel; implement different learning styles to maximize teaching; and mentor students and new staff.
March 2014—BioTheranostics introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provides personalized diagnostic information and therapeutic guidance for metastatic cancer patients.
March 2014—Bio SB launched the Normal Human Tissue Micro Array and the Infectious Disease Cell Line Micro Array. The NH-TMA arrays are available in 11- or 23-core configurations, allowing testing of multiple tissues on one slide, and are validated for use with more than 100 antibodies in immunohistochemistry.
March 2014—Promega launched the QuantiFluor One dsDNA System, a sensitive, dsDNA-specific fluorescent dye for use in research and clinical workflows. The dye system is integrated into the Promega Quantus Fluorometer and GloMax detection instruments but is compatible with any fluorometer capable of measuring the appropriate fluorescence excitation and emission spectra.
March 2014—The Mount Sinai Genetic Testing Laboratory and the Icahn Institute for Genomics and Multiscale Biology at Mount Sinai, New York City, have adopted Qiagen’s Ingenuity Variant Analysis solution for research and translational genomics applications related to characterizing and identifying rare diseases.
